Cargando…
Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis
OBJECTIVE: Cerebrospinal fluid (CSF) biomarkers are shown to facilitate a risk identification of patients with mild cognitive impairment (MCI) into different risk levels of progression to Alzheimer’s disease (AD). Knowing a patient’s risk level provides an opportunity for earlier interventions, whic...
Autores principales: | Michaud, Tzeyu L., Kane, Robert L., McCarten, J. Riley, Gaugler, Joseph E., Nyman, John A., Kuntz, Karen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103924/ https://www.ncbi.nlm.nih.gov/pubmed/29623628 http://dx.doi.org/10.1007/s41669-017-0054-z |
Ejemplares similares
-
The Risk of Incident Mild Cognitive Impairment and Progression to Dementia Considering Mild Cognitive Impairment Subtypes
por: Michaud, Tzeyu L., et al.
Publicado: (2017) -
Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnestic Mild Cognitive Impairment
por: Park, Jung Eun, et al.
Publicado: (2019) -
The effects of cognitive impairment on the multi-scale dynamics of standing postural control during visual-search in older men
por: Zhou, Junhong, et al.
Publicado: (2023) -
Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment
por: Garrett, Stephanie L., et al.
Publicado: (2019) -
Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
por: Liu, Weilin, et al.
Publicado: (2020)